We provide you with 20 years of free, institutional-grade data for FATE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of FATE. Explore the full financial landscape of FATE stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$24,969
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Valamehr Bahram | Sale | -14,466 | $1.06 | $15,396 | 2025-08-05 |
| TAHL CINDY | Sale | -9,037 | $1.06 | $9,573 | 2025-08-05 |
| RedCo II Master Fund, L.P. | Initial | 2025-07-03 | |||
| Bressi Jerome Charles | Grant, award...etc | 65,000 | 2025-01-16 | ||
| TAHL CINDY | Grant, award...etc | 70,000 | 2025-01-16 | ||
| TAHL CINDY | Sale | -5,654 | $1.55 | $8,764 | 2025-01-13 |
| Valamehr Bahram | Sale | -8,705 | $1.54 | $13,406 | 2025-01-13 |
| Bressi Jerome Charles | Sale | -5,980 | $1.55 | $9,269 | 2025-01-13 |
| Redmile Group, LLC | Open Market Purchase | 397,964 | $1.68 | 2024-12-26 | |
| Redmile Group, LLC | Sale | -341,633 | $1.68 | $573,943 | 2024-12-26 |
| Bressi Jerome Charles | Initial | 2024-08-21 | |||
| Xu Yuan | Sale | -633 | $4.23 | $2,678 | 2024-08-07 |
| TAHL CINDY | Grant, award...etc | 200,000 | 2024-07-31 | ||
| Valamehr Bahram | Grant, award...etc | 200,000 | 2024-07-31 | ||
| Redmile Group, LLC | Grant, award...etc | 3,636,364 | $5.5 | 2024-03-25 | |
| Dulac Edward J III | Sale | -2,447 | $7.77 | $19,013 | 2024-03-05 |
| Dulac Edward J III | Sale | -1,849 | $5 | $9,245 | 2024-01-30 |
| TAHL CINDY | Sale | -10,874 | $4.37 | $47,519 | 2024-01-10 |
| Valamehr Bahram | Sale | -11,271 | $4.38 | $49,367 | 2024-01-10 |
| Wolchko J Scott | Sale | -14,391 | $4.37 | $62,889 | 2024-01-10 |
| Dulac Edward J III | Sale | -7,028 | $4.37 | $30,712 | 2024-01-10 |
| Dulac Edward J III | Sale | -5,182 | $3.66 | $18,966 | 2024-01-03 |
| Redmile Group, LLC | Open Market Purchase | 44,630 | $3.72 | 2023-12-28 | |
| Dulac Edward J III | Sale | -1,585 | $3.5 | $5,548 | 2023-12-19 |
| TAHL CINDY | Sale | -24,363 | $2.4 | $58,471 | 2023-11-13 |
| Dulac Edward J III | Sale | -4,718 | $2.8 | $13,210 | 2023-08-21 |
| Xu Yuan | Sale | -632 | $3.71 | $2,345 | 2023-08-07 |
| Dulac Edward J III | Sale | -5,182 | $4.83 | $25,029 | 2023-07-06 |
| Powl Brian T. | Sale | -3,854 | $4.87 | $18,769 | 2023-07-06 |
| Xu Yuan | Sale | -3,460 | $5.58 | $19,307 | 2023-06-15 |
| Redmile Group, LLC | Open Market Purchase | 276,639 | $5.99 | 2023-04-21 | |
| Chu Yu-Waye | Sale | -2,532 | $6.52 | $16,509 | 2023-04-19 |
| Redmile Group, LLC | Open Market Purchase | 25,700 | $6 | 2023-04-17 | |
| Redmile Group, LLC | Sale | -302,339 | $5.84 | $1,765,660 | 2023-04-17 |
| MENDLEIN JOHN | Derivatives Exercise | 28,461 | 2023-01-20 | ||
| Valamehr Bahram | Derivatives Exercise | 423 | 2023-01-13 | ||
| MENDLEIN JOHN | Open Market Purchase | 124,679 | $5.67 | 2023-01-13 | |
| Wolchko J Scott | Sale | -45,907 | $5.24 | $240,553 | 2023-01-11 |
| Valamehr Bahram | Sale | -10,917 | $5.24 | $57,205 | 2023-01-11 |
| TAHL CINDY | Sale | -11,553 | $5.24 | $60,538 | 2023-01-11 |
| Plavsic Mark | Sale | -3,418 | $5.24 | $17,910 | 2023-01-11 |
| Dulac Edward J III | Sale | -7,331 | $5.24 | $38,414 | 2023-01-11 |
| Chu Yu-Waye | Sale | -7,825 | $5.24 | $41,003 | 2023-01-11 |
The information provided in this report about FATE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Fate Therapeutics, Inc(NASDAQ:FATE) 
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, ...
Website: http://www.fatetherapeutics.com
Founded: 2007
Full Time Employees: 178
Sector: Healthcare
Industry: Biotechnology